AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Expands bioprocessing footprint across Asia
Captured microbes are then neutralized on engineered microbicidal surfaces
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Subscribe To Our Newsletter & Stay Updated